RXRX logo
RXRX NASDAQ US

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Healthcare · Biotechnology Website · IPO Apr 2021
$3.11
▲ +$0.05 (+1.63%)
Vol 9.3M
5
Quality Score
fail
Mkt Cap
$2.1B
ROE
-72.7%
Margin
-1637.8%
D/E
1.99
Beta
0.96
52W
$4–$12

Wall Street Consensus

14 analysts · Apr 2026
2
Strong Buy
6
Buy
6
Hold
0
Sell
0
Strong Sell
57.1%
Buy Rating

Price Chart

Similar Stocks

VCEL
Vericel Corp
P/E 139.2
$1.8B
PVLA
Palvella Therapeutics Inc
$1.2B
ZYME
Zymeworks Inc
$2.0B
ANAB
AnaptysBio Inc
$1.3B
NRIX
Nurix Therapeutics Inc
$1.9B
NTLA
Intellia Therapeutics Inc
$1.0B
ARDX
Ardelyx Inc
$1.4B

Earnings

Beat rate: 75.0%
Quarter EPS Est EPS Act Surprise
Dec 2025 $-0.32 $-0.21 +$0.11
Sep 2025 $-0.38 $-0.36 +$0.02
Jun 2025 $-0.36 $-0.41 $-0.05
Mar 2025 $-0.54 $-0.50 +$0.04

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -76.1% -76.1% -76.1% -76.1% -72.7% -72.7%
P/E (TTM) — — — — — —
Net Margin -894.2% -1004.9% -1004.9% -1004.9% -1637.8% -1637.8%
Gross Margin -4.9% -3.5% -3.5% -3.5% -59.0% -59.0%
D/E Ratio 2.50 2.50 2.50 2.50 1.99 1.99
Current Ratio 3.58 3.58 3.58 3.58 4.60 4.60

Key Ratios

ROA (TTM)
-52.5%
P/S (TTM)
48.72
P/B
2.6
EPS (TTM)
$-1.81
CF/Share
$-1.38
Rev Growth 3Y
+79.5%
52W High
$12.36
52W Low
$3.79
$3.79 52-Week Range $12.36

How does RXRX compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

RXRX AAPG ABEO ABOS ABP

RXRX valuation vs Biotechnology peers

P/E ratio
—
▼ 0% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
48.7
▲ 279% above peers (12.9)
vs Peers
vs Industry
Pricier
P/B ratio
2.6
▲ 4% above peers (2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼ 0% below peers (0.0%)
vs Peers
vs Industry
Low yield

RXRX profitability vs Biotechnology peers

ROE
-72.7%
▼ 8% below peers (-67.3%)
vs Peers
vs Industry
In line
Net margin
-1637.8%
▼ 471% below peers (-286.8%)
vs Peers
vs Industry
Weak
Gross margin
-59.0%
▼ 175% below peers (78.6%)
vs Peers
vs Industry
Weak
ROA
-52.5%
▼ 12% below peers (-46.7%)
vs Peers
vs Industry
In line

RXRX financial health vs Biotechnology peers

D/E ratio
2.0
▼ 0% below peers (0.0)
vs Peers
vs Industry
In line
Current ratio
4.6
▲ 4% above peers (4.4)
vs Peers
vs Industry
In line
Beta
1.0
▼ 1% below peers (1.0)
vs Peers
vs Industry
Less volatile

RXRX fundamentals radar

RXRX Peer median Industry

RXRX profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

RXRX vs peers: key metrics

Latest News

No related news yet